Skip to content
Business
Prognosis

Omicron Threat May Be Countered With Extra Dose of Vaccine

  • Series of tests gives early gauge of immunity against variant
  • Cautious optimism that immune protection loss is not complete
Video player cover image
WATCH: Bloomberg Intelligence breaks down the latest findings on the omicron variant and vaccine efficacy.Source: Bloomberg
Updated on

The earliest studies on omicron are in and the glimpse they’re providing is cautiously optimistic: while vaccines like the one made by Pfizer Inc. and BioNTech SE may be less powerful against the new variant, protection can be fortified with boosters.

Research from South Africa, Sweden and Germany, as well as from the companies themselves, shows that omicron does cause a loss of immune protection -- but potentially not a complete one.